NCEL
NewcelX Ltd.
NASDAQ · Healthcare · Biotechnology · CH
$3.34
−0.30%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 5.3K | — | 3.3K | 11.4K | 11.4K |
| Gross Profit | (5.3K) | — | (3.3K) | (11.4K) | (11.4K) |
| Operating Expenses | |||||
| R&D Expense | 1.0M | 1.1M | 422.1K | 5.9M | 9.0M |
| SG&A Expense | 5.4M | 1.3M | 3.2M | 5.9M | 6.5M |
| General & Admin Expense | 3.6M | 1.3M | 3.2M | 5.9M | 6.5K |
| Selling & Marketing Expense | 1.8M | — | — | — | 6.5M |
| Other Expenses | 3.0M | — | 743.8K | — | — |
| Total Operating Expenses | 9.5M | 2.5M | 4.4M | 11.8M | 15.5M |
| Cost and Expenses | 9.5M | 2.5M | 4.4M | 11.8M | 15.5M |
| Operating Income (EBIT) | (10.3M) | (2.5M) | (4.4M) | (11.8M) | (15.5M) |
| Non-Operating | |||||
| Interest Income | — | 369.0K | — | — | 100.87 |
| Interest Expense | 5.8M | 6.0M | 150.0K | 145.2K | 100.9K |
| Net Interest Income | (5.8M) | (5.6M) | (150.0K) | (145.2K) | (100.8K) |
| Other Non-Op Income/Expense | 10.5M | (5.8M) | 2.4M | (365.0K) | (1.0M) |
| Non-Operating Income (excl Interest) | (3.5M) | (182.0K) | (743.8K) | 778.0K | 912.4K |
| EBT (Pre-Tax Income) | 201.5K | (8.3M) | (2.0M) | (12.2M) | (16.5M) |
| Income Tax Expense | 57.4K | — | — | — | — |
| Bottom Line | |||||
| Net Income | 144.1K | (8.3M) | (2.0M) | (12.2M) | (16.5M) |
| Earnings from Cont. Ops | 144.1K | (8.3M) | (2.0M) | (12.2M) | (16.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.9M) | (8.3M) | (4.1M) | (12.2M) | (16.5M) |
| Per Share | |||||
| Basic EPS | ($37.45) | ($2.16) | ($26.30) | ($3.20) | ($8.40) |
| Diluted EPS | ($21.05) | ($2.16) | ($26.30) | ($3.20) | ($8.40) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 3.4M | 3.8M | 75300 | 3.8M | 2.0M |
| Diluted Shares Outstanding | 3.4M | 3.8M | 154328 | 3.8M | 2.0M |
| Profitability Metrics | |||||
| EBITDA | (6.7M) | (2.2M) | (3.6M) | (11.8M) | (15.5M) |
| D&A | 31.4K | 55.0K | 3.3K | 11.4K | 11.4K |
| EBIT | (6.8M) | (2.3M) | (3.6M) | (11.8M) | (15.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025